The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab).
The approval comes as the EC approved Roche’s MabThera (rituximab) for the rare autoimmune disease pemphigus vulgaris (PV) marking the first major advancement in treatment fo the disease in more than 60 years.
Hemlibra, a bispecific antibody targeting factor IXa- and factor X was approved as a treatment in routine prophylaxis of bleeding episodes in severe haemophilia A patients without factor VIII inhibitors.
